US 10,376,476 B2 | ||
Panicein compounds, compositions and uses thereof | ||
Isabelle Mus-Veteau, Valbonne (FR); Olivier Thomas, Galway (IE); Marie-Aude Tribalat, Les Arcs (FR); and Stephane Azoulay, Nice (FR) | ||
Assigned to UNIVERSITE NICE SOPHIA ANTIPOLIS, Nice (FR); and CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris (FR) | ||
Filed by CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris (FR); and UNIVERSITE NICE SOPHIA ANTIPOLIS, Nice (FR) | ||
Filed on Mar. 14, 2018, as Appl. No. 15/920,486. | ||
Application 15/920,486 is a division of application No. 15/522,300, abandoned, previously published as PCT/EP2015/074771, filed on Oct. 26, 2015. | ||
Claims priority of application No. 14306710 (EP), filed on Oct. 27, 2014. | ||
Prior Publication US 2018/0200200 A1, Jul. 19, 2018 | ||
Int. Cl. A61K 31/05 (2006.01); A61K 31/11 (2006.01); A61K 31/353 (2006.01) |
CPC A61K 31/05 (2013.01) [A61K 31/11 (2013.01); A61K 31/353 (2013.01)] | 14 Claims |
1. A method for treating a cancer, for reducing cancer metastasis and/or cancer recurrence in a subject comprising a step of administering to a subject a panicein compound in combination with at least one chemotherapeutic drug, wherein the cancer comprises cancer cells expressing the Patched receptor, and wherein the panicein compound is of formula (I)![]() R1 is H, C1-C6 alkyl, C1-C6 aminoalkyl, C1-C6 hydroxyalkyl, C1-C6 halogenoalkyl or —OR4,
R2 is H or C1-C6 alkyl,
R3 is C1-C6 alkyl, —CH2OR4, —C(═O)R4, —C(═O)OR4, —C(═O)NHR4, or —CH2NHR4,
each R4 is independently —H, or C1-C6 alkyl,
R is:
![]() wherein:
bonds (1) and (2) are independently of each other a single bond or a double bond and bonds (1) and (2) are not simultaneously double bonds,
R5 is present when bond (1) is a single bond, and represents —H, or —OR6, and
when present, each R6 is independently H or a C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and
wherein cancer is selected from a melanoma, a breast cancer, a thyroid cancer, a prostate cancer, an esophagus cancer, a gastric cancer, an ovarian cancer, a pancreatic cancer, a glioma, an adrenocortical carcinoma, a leukemia, a multiple myeloma or a sarcoma; and
wherein the at least one chemotherapeutic drug is selected from cisplatin, docetaxel, doxorubicin, methotrexate, temozolomide, 5-fluorouracil (5-FU), dacarbazine and vemurafenib.
|